Genspera Inc  

(Public, OTCMKTS:GNSZ)   Watch this stock  
Find more results for Genspera, Inc.�
+0.014 (5.00%)
Dec 1 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.26 - 0.29
52 week 0.21 - 1.07
Open 0.26
Vol / Avg. 10,612.00/58,775.00
Mkt cap 10.63M
P/E     -
Div/yield     -
EPS -0.19
Shares 37.50M
Beta 0.39
Inst. own 8%
Sep 9, 2015
Genspera Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -617.39% -214.74%
Return on average equity - -1030.80%
Employees 2 -
CDP Score - -


2511 N Loop 1604 W Suite 204 (3RD Floor
SAN ANTONIO, TX 78258-4633
United States - Map
+1-210-4798112 (Phone)
+1-210-4798113 (Fax)

Website links


GenSpera, Inc. (GenSpera) is an early-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including liver, brain, prostate, renal and other cancers. A prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. The company's technology platform combines a plant-derived cytotoxin with a prodrug delivery system that focuses on the release of the drug within the tumor. Its cancer prodrugs provide a focused therapeutic approach to a range of solid tumors with fewer side effects than those related to current chemotherapy treatments. The Company's lead drug candidate is mipsagargin. The Company's other prodrug candidates include G-114, G-115 and G-301.

Officers and directors

Craig A. Dionne Ph.D. Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer
Age: 57
Russell Richerson Ph.D. Chief Operating Officer, Secretary
Age: 63
Peter E. Grebow Ph.D. Independent Director
Age: 68
Bo Jesper Hansen M.D., Ph.D. Independent Director
Age: 56
Scott V. Ogilvie Independent Director
Age: 61